M
Mathilde C.M. Kouwenhoven
Researcher at VU University Amsterdam
Publications - 68
Citations - 5306
Mathilde C.M. Kouwenhoven is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 23, co-authored 38 publications receiving 4507 citations. Previous affiliations of Mathilde C.M. Kouwenhoven include VU University Medical Center & University Medical Center.
Papers
More filters
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Alba A. Brandes,Martin J.B. Taphoorn,Johan M. Kros,Mathilde C.M. Kouwenhoven,Jean-Yves Delattre,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Pim J. French,Winand N.M. Dinjens,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia,Khê Hoang-Xuan +18 more
TL;DR: The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors, and 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/ 19q-deleted tumors.
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent,Antoine F. Carpentier,Alba A. Brandes,Marc Sanson,Martin J B Taphoorn,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,Laslo Sipos,H. Haaxma-Reiche,Johannes M. Kros,Mathilde C.M. Kouwenhoven,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia +16 more
TL;DR: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in anaplastic oligodendroglioma, and combined loss of 1p/19q identifies a favorable subgroup of oligodENDroglial tumors.
Journal ArticleDOI
Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma
Anastasia Murat,Eugenia Migliavacca,Thierry Gorlia,Wanyu L. Lambiv,Tal Shay,Marie-France Hamou,Nicolas de Tribolet,Luca Regli,Wolfgang Wick,Mathilde C.M. Kouwenhoven,Johannes A. Hainfellner,Frank L. Heppner,Pierre-Yves Dietrich,Yitzhak Zimmer,J. Gregory Cairncross,Robert-Charles Janzer,Eytan Domany,Mauro Delorenzi,Roger Stupp,Monika E. Hegi +19 more
TL;DR: This study provides first clinical evidence for the implication of a "glioma stem cell" or "self-renewal" phenotype in treatment resistance of glioblastoma.
Journal ArticleDOI
Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology
Lonneke A.M. Gravendeel,Mathilde C.M. Kouwenhoven,Olivier Gevaert,Johan J. de Rooi,Andrew P. Stubbs,J Elza Duijm,Anneleen Daemen,Fonnet E. Bleeker,Linda B. C. Bralten,Nanne K. Kloosterhof,Bart De Moor,Paul H. C. Eilers,Peter J. van der Spek,Johan M. Kros,Peter A. E. Sillevis Smitt,Martin J. van den Bent,Pim J. French +16 more
TL;DR: The data provide compelling evidence that expression profiling is a more accurate and objective method to classify gliomas than histologic classification, and molecular classification therefore may aid diagnosis and can guide clinical decision making.
Journal ArticleDOI
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent,Alba A. Brandes,Roy Rampling,Mathilde C.M. Kouwenhoven,Johan M. Kros,Antoine F. Carpentier,Paul Clement,Marc Frenay,Mario Campone,Jean-François Baurain,Jean-Paul Armand,Martin J.B. Taphoorn,Alicia Tosoni,Heidemarie Kletzl,Barbara Klughammer,Denis Lacombe,Thierry Gorlia +16 more
TL;DR: Erlotinib has insufficient single-agent activity in unselected GBM, and the use of enzyme-inducing anticonvulsants significantly increased erlot inib clearance, but pharmacokinetic findings were not related to outcome.